Assessment of the Effects of Crude Metabolic Extracts (Leaf and Twig) of Loranthus Micranthus on Streptozotocin Induced Diabetic Rats

Bodun Oye Olakanmi 1, Olufunke Esan Olorundare 1, Saheed Oanrewaju Afolabi 1, Anoka Njan 1, Olugbenga Akinola 1, Olatunde Akanbi 1, Amase Nyamngee 1, Adejuwon Adeneye 1, Ezekiel Olugbenga Iwalewa 1, James Mukasa. Ntambi 1

1Department of Pharmacology and Therapeutics, College of Health Sciences, University of Ilorin, Ilorin, Nigeria
2Department of Veterinary Pathology, Faculty of Veterinary Medicine, University of Ilorin, Nigeria.
3Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Health Sciences, University of Ilorin, Ilorin, Nigeria.
4Department of Pharmacology, Faculty of Basic Medical Sciences, College of Medicine, Lagos State University, Lagos, Nigeria.
5Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Nigeria.
6Departments of Biochemistry and Nutritional Sciences, University of Wisconsin-Madison, WI, USA.

*Corresponding Author: Bodun Oye Olakanmi, Department of Pharmacology and Therapeutics, College of Health Sciences, University of Ilorin, Ilorin, Nigeria.

Received date: November 01, 2019; Accepted date: December 30, 2019; Published date: January 05, 2020

Copyright: © 2020 Bodun Oye Olakanmi, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The antidiabetic effects of crude methanolic extracts of the leaf and twig of Loranthus micranthus was evaluated in Wister rats. To assess this, data were obtained for the determinant parameters of diabetic complications.

Streptozotocin was administered for induction of diabetes; diabetic state was confirmed by persistent hyperglycemia (FBG ≥ 300mg/dl) at 72 hours post induction. In vitro inhibitory activity on α-amylase and α-glucosidase was assayed. Serum insulin, TNF-α, Total cholesterol, HDL, LDL, TG, atherogenic index, liver glycogen and glycated haemoglobin were evaluated. Histology of the pancreas was assessed.

Phytochemical analysis revealed the presence of unique compounds in both extracts. In vitro assay showed inhibitory effects of both extracts on α-amylase and α-glucosidase activity. Hyperglycemia was controlled in both extract-treated groups comparable to glibenclamide. Weight loss after diabetic induction was ameliorated in extracts treated groups; serum insulin level of the extracts-treated and glibenclamide treated-group were higher than the diabetic control group. Serum TNF-α level of extracts-treated and glibenclamide-treated groups were significantly lower than the diabetic control group. Glycated hemoglobin levels of diabetic control group were higher than the extracts treated and glibenclamide group. Dyslipidemia observed in the diabetic control group were ameliorated in all extract-treated groups; atherogenic index of diabetic control group was higher than extracts-and-glibenclamide treated groups. Histopathological assessment showed that the leaf and twig extracts of Loranthus micranthus may possess β cell regenerating activity. Findings from this study suggest that the leaf and twig extracts of Loranthus micranthus ameliorate symptoms and complications of streptozotocin-induced diabetes in rats.

Keywords: Loranthus micranthus, GC-MS, hyperglycemia, atherogenic index, pancreas, glycated-hemoglobin
1. Introduction

Diabetes mellitus (DM) is a group of metabolic diseases characterized by high blood sugar levels over a prolonged period (persistent hyperglycemia), due to defects in secretion of insulin or biologic action of insulin [1,2]. Prolonged diabetes causes many complications, which can be acute or chronic complications. These has been linked to severe dysfunction and damage of various body organs: the eyes, kidneys, nerves, heart, blood vessels; and results annually in more than 5% deaths worldwide [3,1]. Persistent hyperglycemia has been reported to lead to the generation of free radicals through the formation of Schiff base and amadori products, which are implicated in the end organ damage caused by diabetes mellitus [4].

In 2017, it was estimated that 451 million (age 18-99 years) are living with diabetes worldwide [5]. These figures were expected to increase to 693 million by 2045 [5]. Approximately 5 million deaths worldwide were attributable to diabetes in 2017 within 20-99 years age range [6, 7]. The global healthcare expenditure on people with diabetes was estimated to be USD 850 billion in 2017 [8]. These new estimates of diabetes prevalence, deaths and healthcare expenditure present a large social, financial and health system burden across the world [5].

Diabetic patients with raised plasma glucose levels have proportionally more glycation occurring both intracellularly and extracellularly thereby necessitating the need to treat these complications as an integral part of the clinical stratification of diabetic patients [9,10]. Previous studies suggested that inhibition of the production of advanced glycated end products (AGEs) or blockade of their downstream signaling pathway to be promising targets for treatment of patients with diabetic complications [10,11,12,13].

One important complication of diabetes is the elevation of atherogenic risk, as diabetic dyslipidemia is a prominent contributor for the development of cardiovascular diseases [14]. Components of the immune system are altered in obesity and accompanying T2D, with striking changes occurring in the adipose tissue, liver, pancreatic islets, the vasculature and circulating leukocytes. These immunological changes include altered levels of specific cytokines and chemokines, changes in the number and activation state of various leukocyte populations, increased apoptosis and tissue fibrosis. Together, these changes suggest that inflammation participates in the pathogenesis of T2D [15, 16].

Conventional antidiabetic drugs are both costly and associated with many adverse effects [17]. Thus, the search for safer and affordable antidiabetic drugs has led to studies investigating several plants for such activity. Among plants with potent antidiabetic principles is the hemi parasite, Loranthus micranthus (L. micranthus) which is one of the species of African mistletoe found in Nigeria [18]. Mistletoe species show varying phytochemical components and bioactivity which is dependent on the host plant. The influence of the host tree on the antidiabetic activity has been reported by a group of researchers [18,19]. Studies have also shown seasonal variations in the antidiabetic activity of this semi parasite [20,21]. African mistletoe parasitic on different host trees has been used for various medicinal purposes and ethnomedically as antidiabetic, antihypertensive and antimicrobial agent [22].

The aim of the present study is to evaluate the effect of crude methanolic extracts of leaf and twig of Loranthus micranthus separately, for their antidiabetic activities and their potentials in ameliorating some parameters of diabetic complications.

2. Materials and Methods

2.1 Plant Materials

Fresh leaves and twigs of African mistletoe, Loranthus micranthus, were harvested during the dry season at Egbo Area in Ilaro, Ogun State, Nigeria. Plant identification was done at the Department of Plant Biology, University of Ilorin, Ilorin, Nigeria. A specimen was deposited at the herbarium and voucher number ULLH/001/1260 was allocated to the sample. Plants materials were dried under the shade, at room temperature for 10days. The dried plants were separated into leaves and twigs and separately pulverized using mortar and pestle and weighed. The resulting powder was macerated in 95% methanol for 72hours.

2.2 Chemicals

Streptozotocin (STZ) (Sigma Aldrich, USA), n-nitrophenyl α – d-glucopyranoside, n-nitrophenyl β –d – glucopyranoside, α- glucosidase, α-amylase, carboxy methyl cellulose (Elabscience, UK), Elisa Rat insulin kit Elabscience, UK, Elisa Rat glycated hemoglobin kit, Elabscience, UK, Elisa Rat TNF-α kit, Elabscience, UK, HDL-Cholesterol Assay kit, Elabscience, UK, Cholesterol CHOD-PAP Assay kit, Elabscience, UK, Triglyceride GPO-PAP Assay kit, Elabscience, UK, Glycogen Assay kit (Sigma-Aldrich), USA, Glibenclamide 5mg (Daonil), Aventis Pharma Ltd, Glucose, PBS, citrate buffer.

2.3 Preparation of Extracts

Cold maceration was used for the extraction, in which 1kg each of ground dried leaves and twigs were soaked in 3.5liters of 95% aqueous methanol. The set up was intermittently shaken vigorously for 72hours. The (residue) was removed by clarification using muslin which was discarded, and later filtered through Whatman N1 filter paper. The filtrates were then dried in-vacuo using a rotary evaporator at 40°C. The resultant semi-solid was then concentrated on a water bath shaker at 40°C for 60hrs.

2.4 Gas Chromatography Mass Spectrometer (GC-MS)

2.4.1 Gas Chromatography (GC) Analysis

Gas Chromatography (GC) analyses were performed on an Orion micromat 412 double focusing gas chromatography system fitted with two capillary columns coated with Cp-Sil 5 and Cp-Sil 9 (fused silica, 25µm × 0.25mm, 0.15µm film thickness) and flame ionization detector (FID). The empty glass of material injected was 0.2mL, and the split ratio was 1:30. Oven temperature was programmed from 50-230°C at 3°C/min using helium as a carrier gas. Injection and detector temperature were maintained at 200°C and 250°C, respectively. Qualitative data were obtained by electronic integration of FID area percent without the use of correction factors.

2.4.2 Mass Spectrometry (MS) Analysis

In MS analysis, a Hewlett – Packed HP 5890A GC, interfaced with a VG analytical 70-250s double focusing mass spectrometer were used. Helium was used as the carrier gas at 1.2ml/min. The MS operating conditions were: ionization voltage 70ev, ion source 230°C. The GC was fitted with a 25µm × 0.25mm, fused silica capillary column coated with C-5 – Sil 5. The film thickness was 0.15µm; the GC operating conditions were: oven temperature programmed from 50°C to 230°C at 3°C/min using helium as a carrier gas. Injection and detector temperature were maintained at 200 °C and 250 °C, respectively. Qualitative data were obtained by electronic integration of FID area percent without the use of correction factors.
of series of n-alkanes) and mass Spectra with those of authentic samples and with data from literature [23,24].

2.5. Acute toxicity study

Twenty-four female Wistar rats divided into four groups receiving *L. micranthus* twig and leaf extracts at doses of 100, 250, 500 and 1000mg/kg daily for a period of 2 weeks. Each group consisted of three rats for each dose employed. The animals were observed during the first hour continuously and then every hour for six hours, thereafter at 12 hours and 24 hours. Animals were then observed every 24 hours for 2 weeks for any physical signs of toxicity such as writhing, gasping, palpitation and decreased respiratory rate or mortality.

2.6 Experimental Animals

Fifty-five (55) female rats, about 8 weeks old, weighing between 100-120g were used for the study. Animals were housed in Animal House Facility in the Central Research Laboratory, University of Ilorin, Ilorin, Nigeria, for 7 days under standard conditions of appropriate ventilation, temperature of 22-25°C, relative humidity of 50% and 12hours day and night cycle. Animals were fed with standard rat chow and water was supplied *ad libitum* throughout the acclimatization period. Stressful conditions were avoided all through the experimental period.

2.7 Induction of Diabetes

Diabetes was induced in 40 rats by an intraperitoneal injection of a fresh solution of a single dose of streptozocin (STZ) Sigma Aldrich Chemicals, USA. The solution was prepared by dissolving STZ in 0.1M sodium citrate buffer, pH4.5. Animals were administered with a dose of 65mg/kg body weight after being fasted overnight, according to the method described by Lenzen, 2008 [25]. Immediately after diabetic induction, animals were given 50% glucose solution in their drinking water *ad libitum*. Animals with fasting blood Glucose level (FBG) between 340-650mg/dl were considered diabetic and selected for the diabetic groups. For the purpose of treatment, the rats were randomly divided into the following experimental groups:

2.8 Experimental Groups

Group 1 = Normal control (n=5)
Group 2 = Normal rats + 500mg/kg leaf extract (n=5)
Group 3 = Normal rats + 500mg/kg twig extract (n=5)
Group 4 = Diabetic rats + 500mg/kg leaf extract (n=5)
Group 5 = Diabetic rats + 500mg/kg twig extract (n=5)
Group 6 = Diabetic rats + Distilled water (n=5)
Group 7 = Diabetic rats + 5mg/kg glibenclamide (n=5)
Group 8 = Diabetic rats + 250mg/kg leaf extract (n=5)
Group 9 = Diabetic rats + 250mg/kg twig extract (n=5)
Group 10 = Diabetic rats + 125mg/kg leaf extract (n=5)
Group 11 = Diabetic rats + 125mg/kg twig extract (n=5)

2.9 Body Weight Evaluation

Weights of the experimental animals were obtained at the beginning of the study- day 0, day 7, day 10 and day 14 of the experiment. Weights obtained were analyzed statistically.

2.10 Plasma Glucose Level

Plasma glucose level was determined by Accucheck plus GCT Glucometer (Roche, USA). The monitor of the glucometer device uses a reflectance photometer for measuring the intensity of the color formed at the end of the reaction. This measurement uses software which translated the intensity to the corresponding glucose values. The fasting blood glucose (FBG) of all animals was measured at day zero before diabetic induction to obtain baseline glucose level for all the rats; and thereafter, following the induction of diabetes and throughout the treatment period. Plasma glucose was determined 72hours after STZ injection for confirmation of diabetes. In addition, blood glucose was measured weekly for a period of 2 weeks using the glucometer method discussed earlier, following which the animals were sacrificed.

2.10 Oral Glucose Tolerance Test

Blood Glucose level of 16 hours fasted rats was determined, and the value used as zero time of the test. At the end of the experiment, i.e. after the last dose of the vehicle, or glibenclamide or extracts, glucose solution (50%) at a dose of 2g/kg was given by oral intubation, according to the methods described by Ayala et al., (2010) [26]. Blood samples were taken at 30, 60, 90 and 120 minutes after glucose loading and blood glucose level determined with one touch glucometer (Accucheck Plus GCT, Glucometer). Plots of the values of blood glucose level (mg/dL) versus the time intervals (min) were constructed and the area under the curve (AUC) calculated using the Trapezoidal method. The AUCs for each group was compared and tested for significance against the diabetic-un-treated group and this represented the tissue glucose utilization.

2.11 In-Vitro Antidiabetic Assays

2.11.1 α - Amylase Inhibitory Activity Assay

The effect of crude methanolic extracts of *L. micranthus* (leaf and twig) on α - amylase activity was determined by the method described by Ali et al., 2006 [27]. Briefly, 50μl of α-amylase (5U/ml) was pre-incubated for 20 min with 50μl aliquots of extracts. The reaction was started by the addition of 50μl starch (0.5%) dissolved in 20mM phosphate buffer at pH 6.9. The reaction mixture was incubated for a further 20 min at 37°C and the catalytic reaction terminated by addition of 2.0 ml of DNS reagent (1% 3, 5-dinitrosalicicyclic acid (DNS) and 12% sodium potassium tartrate in 0.4 M NaOH). The reaction mixture was heated for 15 min at 100°C. α-amylase activity was determined by spectrophotometric measurement of the absorbance at 540 nm. Percentage α-amylase inhibition was calculated according to the following formula;

\[ \frac{(A_0 - A_t)}{A_0} x 100 \]

where, *A₀* was the absorbance of the blank (without extract) and *Aₜ* was the absorbance in the presence of the extract.

2.11.2 α - Glucosidase Inhibitory Activity

The inhibitory effect of *L. micranthus* extracts on α-glucosidase activity was determined according to the chromogenic method described by Kim et al. (2005) [28]. Briefly, α-glucosidase (5 units) was pre-incubated with 20 μg/ml of the different extracts for 15 min. Para-nitrophenylglucopyranoside (PNPG) (3mM) dissolved in 20 mM phosphate buffer, pH 6.9, was added to start the reaction. The reaction mixture was further incubated at 37°C for 20 min and stopped by addition of 2 ml of 0.1 M Na₂CO₃. Using a spectrophotometer, the α-glucosidase activity was measured.
activity was determined by measuring the yellow colored p-nitrophenol released from PNPG at 400 nm. Percentage α-glucosidase inhibition was calculated according to the following:

\[
\frac{(A_0 - A)}{A_0} \times 100\% \text{ where, } A_0 \text{ was the absorbance of the control (blank, without extract) and } A \text{ was the absorbance in the present extract.}
\]

2.11. Sample Collection and Handling

At the end of the 14-day treatment blood samples were drawn 3 hours after the last dose from the orbital sinus of rats, under light ether anesthesia into two different tubes (heparin and plain bottles) for each animal respectively. The samples were immediately centrifuged at 0°C/1000g for 15min for separation of serum. The resulting serum samples was separated and kept at -20°C until used for required analysis.

2.13. Estimation of Plasma Insulin Level

Insulin concentration was determined by radioimmunoassay procedure using a Rat INS (Insulin) ELISA Kit (Elabscience, E-EL-R2466, 96T). This assay has a high specificity as it recognizes natural and recombinant Rat INS without significant cross-reactivity or interference between Rat INS and analogues. The ELISA kit uses Sandwich-ELISA as the method. Sample and reagent preparation was done according to the manufacturer’s manual using serum samples. Spectrophotometric measurements were done at a wavelength of 450 nm ± 2 nm. Concentration of insulin in the samples was calculated by comparing the OD of the samples to the standard curve.

2.14. Estimation of Tissue Glycogen

At the end of the experiments, livers collected were weighed and divided into 2 sample tubes, for liver glycogen assay and histopathological evaluation. Liver samples for glycogen assay were immediately frozen in phosphate buffered saline prior to the assay. Glycogen content of liver was assayed using glycogen assay kit (Sigma-Aldrich, 3050 Spruce Street, ST. Louis, MO 63103 USA). The coupled enzyme assay produces a colorimetric (570 nm) product, proportional to the glycogen concentration present in the samples.

2.15. Estimation of Plasma Lipid Profile

Blood lipid (TC, HDL and TG) levels were determined using spectrophotometric assay techniques. Assays were conducted according to the manufacturer’s manual. Serums of all the animals in different groups were analyzed.

2.15.1 Total Cholesterol

Total cholesterol in serum was assayed using Elabscience Total Cholesterol Assay Kit. The assay is based on the enzyme driven reaction that quantifies both cholesterol esters and free cholesterol. Cholesterol esters were hydrolyzed via cholesterol esterase to cholesterol, which was subsequently oxidized by cholesterol oxidase to the ketone cholest-4-en-3-one and hydrogen peroxide. Hydrogen peroxide was detected with a high specificity colorimetric probe. Horseradish peroxidase (HRP) catalyzes the reaction between the probe and hydrogen peroxide, which was bound in a 1:1 ratio. Samples were compared to a known concentration of cholesterol standard in a 96-well microtiter plate. Samples and standards were incubated for 45 mins and then read on a standard 96-well colorimetric plate reader, at absorbance of 540 nm. The concentration of cholesterol in each sample was calculated by comparing the sample absorbance values to the cholesterol standard curve.

2.15.2. Serum Triglycerides Concentration

Triglycerides level in serum was assayed using GPO-PAP method (Elabscience TG Assay Kit). All reagents were ready to use and were mixed according to the manufacturer’s manual. The mixture was measured after incubating at 37°C for 5 min. Absorbance of sample against reagent blank was read at 550nm within 60 min. Triglycerides concentration in the sample was calculated as follows:

\[
A_{\text{sample}} \times \text{concentration of Standard} = \text{Triglycerides concentration of } A_{\text{Stand}}
\]

(where \(A_{\text{sample}} \) and \(A_{\text{standard}}\) absorbance of sample and standard respectively)

2.15.3. High Density Lipoprotein Cholesterol (HDL-C) Assay

High Density Lipoprotein Cholesterol (HDL-C) in the serum of each sample was assayed according to the manufacturer’s manual using direct method, with Elabscience High Density Lipoprotein Cholesterol (HDL-C) assay kit. 10µl of serum was mixed with reagents R1 and R2. The solutions were mixed thoroughly and incubated at 37°C for 5 minutes. The absorbance was read at 546nm wavelength. HDL Cholesterol concentration in the samples was calculated according to the calculation formula in the manual.

\[
\text{Absorbance of sample} - \text{Blank} = \text{HDL-C concentration of Standard} = \frac{X \text{ concentration of standard}}{X \text{ concentration of standard}}
\]

(Absorbance of standard – Blank).

2.15.4. LDL Cholesterol

LDL-Cholesterol was estimated by using the formula of Friedewald et al., 1972 [29]:

LDL – Cholesterol = Total cholesterol – HDL-Cholesterol – TG/5.

2.15.5. Atherogenic Index: The Atherogenic index (AI) was calculated according to the formula of Harnafiet al., 2014 [30].

\[
\text{AI} = \text{Total Cholesterol} – \text{HDL-Cholesterol}
\]

2.16. Glycated Hemoglobin (HbA1c)

Glycated hemoglobin was assayed from the whole blood using HbA1c ELISA kit (Elabscience) which employed the competitive enzyme immunoassay technique, utilizing a monoclonal anti-HbA1c antibody and an HbA1c-HRP conjugate. The intensity of color formed was measured spectrophotometrically at 450nm on a microplate reader. The intensity of the color was inversely proportional to the HbA1c concentration. A standard curve was plotted relating the intensity of the color (O.D.) to the concentration of standards. The HbA1c concentration in each sample was determined from this standard curve.

2.17. Tumor Necrotic Factor-A (TNF-α)
TNF-α was assayed using rat TNF-α ELISA Kit (Elabscience, E-EL-R0019). Standards and samples were prepared according to the manufacturer’s specification. The prepared solutions were added to the appropriate micro ELISA plate wells and combined with specific antibody for TNF-α and Avidin-Horseradish Peroxidase (HRP) conjugate and were incubated. The free unbound components were washed away. Only the wells that contained TNF-α, biotinylated detection antibody and Avidin-HRP conjugate appeared blue. The enzyme-substrate reaction was terminated by addition of H₂SO₄ which turned the blue colour yellow. The optical density (OD) was measured spectrophotometrically at a wavelength of 450nm. The OD values obtained were proportional to the concentration of TNF-α in each microplate well. The concentration of TNF-α in the samples was calculated by comparing the OD of samples was determined from the standard curve.

2.18. Histopathology
Pancreas and pancreatic tissues within the duodenal loop of each rat in all groups were taken out immediately after animals were sacrificed, at the termination of the experiments. These were fixed in 10% phosphate buffered formaldehyde solution for at least 48 hours. The tissues were later cut into 0.5x1cm in diameter each using scalpel blade and processed using an automatic tissue processor. Processed tissues were embedded later in buffered formaldehyde solution for at least 48 hours. The tissues were cut 0.5x1cm in diameter each using scalpel blade and processed using an automatic tissue processor. Processed tissues were embedded using MP3 tissue embedding center. A rotary microtome machine was used to cut sections which were mounted using dextrin plasticizer xylene and were incubated. The free unbound components were washed away. Only the wells that contained TNF-α, biotinylated detection antibody and Avidin-HRP conjugate appeared blue. The enzyme-substrate reaction was terminated by addition of H₂SO₄ which turned the blue colour yellow. The optical density (OD) was measured spectrophotometrically at a wavelength of 450nm. The OD values obtained were proportional to the concentration of TNF-α in each microplate well. The concentration of TNF-α in the samples was calculated by comparing the OD of samples was determined from the standard curve.

2.19. Statistical Analysis

Data obtained in the present study were subjected to statistical analysis using GraphPad Prism application version 6. The means, standard errors of means and standard deviations were obtained as summary statistics. The obtained summary statistics were subjected to one-way analysis of variance (ANOVA) using the Tukey’s post-hoc test to check for significant relationship between experimental groups. The data were pictorially presented as line graphs and bar charts with bars and error bars representing the means and standard errors of means respectively. Statistical significance was set at p value less than 0.05.

3. Results

3.1. Phytochemical Analysis

Qualitatively, 48 and 40 compounds were found to be prominent in leaf and twig extract of L. micranthus respectively. Thirteen of the compounds were commonly found in both leaf and twig of L. micranthus. The similar compounds are Cyclobutanol, 1,4-Dimethyl hexyl alanine, Piperazine, 4-Butyl phenol, N-(2-Hydroxy benzyl) alanine, Palmitic acid methyl ester, Ethyl hexadecanoate, 2-Undecyl phenol, Phytol, Methyl stearate, Methyl linoleate, Ethyl oleate and Squalene. Quantitatively, Palmitic acid methyl ester, Phytol, Methyl stearate and Methyl linoleate were found in higher quantity in the leaf than the twig extracts of L. micranthus. However, Cyclobutanol, 1,4- Dimethyl hexyl alanine, Piperazine, 4-Butyl phenol, N-(2-Hydroxy benzyl) alanine, Ethyl hexadecanoate, 2-Undecyl phenol, Ethyl oleate and Squalene were found in significant amounts in the twig compared to the leaf extract of African Mistletoe.

3.2 Mean Body Weight
<table>
<thead>
<tr>
<th>Compound</th>
<th>CAS No.</th>
<th>PMR Data</th>
<th>Functional Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coumaran</td>
<td>1036</td>
<td>63 77 91 105 120</td>
<td>-C=O, -C=C</td>
</tr>
<tr>
<td>-limonene diepoxide</td>
<td>1128</td>
<td>41 43 67 83 95</td>
<td>-C-O-C</td>
</tr>
<tr>
<td>-Campholenal</td>
<td>1153</td>
<td>81 93 108 119 137</td>
<td>-CHO, -C=C</td>
</tr>
<tr>
<td>2-Propyl malonic acid</td>
<td>1266</td>
<td>41 44 6073 87</td>
<td>-COOH</td>
</tr>
<tr>
<td>D-2-Deoxyribose</td>
<td>1274</td>
<td>27 31 44 57 73</td>
<td>-OH,-C=O</td>
</tr>
<tr>
<td>P-butyl phenol</td>
<td>1312</td>
<td>77 91 107 121 123</td>
<td>OH,-C=O</td>
</tr>
<tr>
<td>2,3-Bis(1, methylallyl)</td>
<td>1328</td>
<td>92 97 124 126 150</td>
<td>pyrolidine</td>
</tr>
<tr>
<td>3-Butyl indolizidine</td>
<td>1393</td>
<td>96 110 124 138 152</td>
<td>-NH</td>
</tr>
<tr>
<td>P-Coumaric alcohol</td>
<td>1464</td>
<td>94 107 121 131 150</td>
<td>-OH,-C=C</td>
</tr>
<tr>
<td>Methyl alpha-L-fuco</td>
<td>1471</td>
<td>43 60 74 87 100</td>
<td>-OH pyranoside</td>
</tr>
<tr>
<td>2,3-Dimethyl-2(3- oxobutyl)</td>
<td>1521</td>
<td>41 439 82 97</td>
<td>-C=O</td>
</tr>
<tr>
<td>Trimethyl[1-methyl</td>
<td>1533</td>
<td>73 87 101 117 129</td>
<td>dodecyl]oxy] Silane</td>
</tr>
<tr>
<td>Methyl isomystirate</td>
<td>1615</td>
<td>57 74 87 101 115</td>
<td>-COO Cyclohexanone</td>
</tr>
<tr>
<td>3-Oxo-alpha-ionol</td>
<td>1627</td>
<td>79 95 108 123 137</td>
<td>-OH,-C=O -C=C-C=</td>
</tr>
<tr>
<td>Methyl 3,4, trimethoxy</td>
<td>1628</td>
<td>155 168 195 196 226</td>
<td>C=C</td>
</tr>
<tr>
<td>Benzoate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methyl tetradecanoate</td>
<td>1715</td>
<td>41 55 57 74 87</td>
<td>-COO</td>
</tr>
<tr>
<td>Hexahydrofarnesyl acetone</td>
<td>1754</td>
<td>41 435 87 115</td>
<td>-COO</td>
</tr>
<tr>
<td>Sulfurous acid, isohexyl</td>
<td>1773</td>
<td>83 85 101 137 167</td>
<td>Hexyl ester</td>
</tr>
<tr>
<td>Methyl pentadecanolate</td>
<td>1779</td>
<td>57 74 87 101 115</td>
<td>-COO</td>
</tr>
<tr>
<td>N-(2-Hydroxybenzyl)</td>
<td>1803</td>
<td>4456 77 95 107</td>
<td>alanine</td>
</tr>
<tr>
<td>Palmitic acid, methyl ester</td>
<td>1878</td>
<td>57 7487 101 115</td>
<td>-COO</td>
</tr>
<tr>
<td>3,5,11,15-Tetramethyl-1-Hexadecen-3-ol</td>
<td>1899</td>
<td>57 71 95 109 123</td>
<td>C=C,-OH</td>
</tr>
<tr>
<td>Farnesyl acetone</td>
<td>1902</td>
<td>41 43 6981 95</td>
<td>-C=O</td>
</tr>
<tr>
<td>Heptadecanoic acid methyl</td>
<td>1978</td>
<td>57 7487 101 115</td>
<td>-COO ester</td>
</tr>
<tr>
<td>Ethyl hexadecanoate</td>
<td>1978</td>
<td>57 73 88 101 115</td>
<td>-COO</td>
</tr>
<tr>
<td>2-Undecyl phenol</td>
<td>2008</td>
<td>77 91 107 121 131</td>
<td>-OH,-C=C</td>
</tr>
<tr>
<td>Phytol</td>
<td>2045</td>
<td>41 57 71 95 111</td>
<td>-OH</td>
</tr>
<tr>
<td>Methyl stearate</td>
<td>2077</td>
<td>41 43 74 87 101</td>
<td>-COO</td>
</tr>
<tr>
<td>Methyl linoleate</td>
<td>2093</td>
<td>41 55 67 81 95</td>
<td>-COO</td>
</tr>
<tr>
<td>Ethyl oleate</td>
<td>2185</td>
<td>4155 69 83 88</td>
<td>-COO</td>
</tr>
<tr>
<td>Methyl-18-methyl nona</td>
<td>2212</td>
<td>57 74 87 101 115</td>
<td>-COO decanoate</td>
</tr>
</tbody>
</table>
Table 1: Shows the identities, retention indices, percentage composition and mass spectra data of the constituents of methanolic extract of *L. micranthus*. In the Table, 48 compounds were identified from their mass spectra, the number represented 94.9% of the leaf.

<table>
<thead>
<tr>
<th>Constituent</th>
<th>Retention Index</th>
<th>Mass Spectra Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methyl heneicosanoate</td>
<td>2375</td>
<td>43 57 74 87 111 -COO</td>
</tr>
<tr>
<td>Methyl docosanoate</td>
<td>2475</td>
<td>43 57 74 87 101 -COO</td>
</tr>
<tr>
<td>Methyl-8, 11, 14-docosa</td>
<td>2499</td>
<td>41 55 67 81 95 -COO trienoate</td>
</tr>
<tr>
<td>Glycerol-2-monooleate</td>
<td>2705</td>
<td>41 55 69 81 95 -COO, -OH</td>
</tr>
<tr>
<td>Lanosterol</td>
<td>2882</td>
<td>41 43 69 81 95 -OH</td>
</tr>
<tr>
<td>Squalene</td>
<td>2914</td>
<td>41 43 69 81 95</td>
</tr>
<tr>
<td>dl- -Tocopherol</td>
<td>3149</td>
<td>121 136 149 165 177 -OH, -C=C</td>
</tr>
<tr>
<td>Phthalic acid, isobutyl</td>
<td>3364</td>
<td>121 133 149 165 170 Octa decyl ester</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>94.9</strong></td>
<td></td>
</tr>
</tbody>
</table>

### 3.3 Effect of Extracts on Fasting Blood Glucose

![Graph showing fasting blood glucose levels](image)

**Figure 1:** Chart A and B showing the fasting blood sugar of the experimental animals on day 1 (after diabetes induction), day 7 (7 days treatment) and day 14 (14 days treatment) for leaf and twig extract respectively. There was hyperglycemia in all STZ treated groups after diabetic induction. STZ-only group showed persistent hyperglycemia all through the experiment.

Treatment groups (Glibenclamide, LML and LMT extracts) showed adequate glycemic control at all concentrations used. CTR= control, LML= *L. micranthus* leaf extract, LMT= *L. micranthus* twig extract, STZ= streptozotocin, GL= glibenclamide.

* is p value < 0.05 relative to control group. Data is presented as mean (bars) ± standard error of mean (error bars).

### 3.3 Biochemical Parameters
3.3.1. In Vitro Assay

The inhibitory activity of the leaf and twig extract of *L. micranthus* on α-amylase and α-glucosidase enzyme activity were evaluated *in vitro* at different extract concentrations. The result obtained was analyzed and are presented in the line graphs below.

![Graphs A, B, C, and D](image)

Figure 3: Chart A, B, C and D showing levels of liver glycogen, serum insulin, glycated haemoglobin and tumour necrosis factor-α in the experimental animals of various groups. STZ Only and GL treatment groups showed significantly lower (p<0.05) liver glycogen levels compared with LML and LMT treated groups. Insulin level was significantly lower (p<0.05) in STZ only group compared with all other groups. Glycated hemoglobin was significantly higher (p<0.05) in STZ only group. Tumor necrotic factor-α was significantly higher (p<0.05) in STZ only group.

**CTR**= control, **LML**= *L. micranthus* leaf extract, **LMT**= *L. micranthus* twig extract, **STZ**= streptozotocin, **GL**= glibenclamide. Data is presented as mean (bars) ± standard error of mean (error bars). * is significant level of p< 0.05 relative to the STZ group.

### LIPID PROFILE

<table>
<thead>
<tr>
<th>GROUPS</th>
<th>Triglycerides (mg/dl)</th>
<th>Total cholesterol (mg/dl)</th>
<th>High density lipoprotein (mg/dl)</th>
<th>Low density lipoprotein (mg/dl)</th>
<th>Atherogenic index (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONTROL</td>
<td>176.12±16.41</td>
<td>102.21±4.00</td>
<td>35.65±5.08</td>
<td>30.05±3.42</td>
<td>1.94±0.30</td>
</tr>
<tr>
<td>STZ only</td>
<td>653±111.08*</td>
<td>216.22±10.12*</td>
<td>39.34±7.64</td>
<td>69.41±11.73*</td>
<td>6.70±1.08*</td>
</tr>
<tr>
<td>LML500</td>
<td>133.00±6.56*</td>
<td>118.23±3.11</td>
<td>58.56±3.24*</td>
<td>33.36±1.17</td>
<td>1.04±0.07</td>
</tr>
<tr>
<td>LMT500</td>
<td>158.00±27.56*</td>
<td>114.00±4.12</td>
<td>51.12±5.34*</td>
<td>32.08±1.84</td>
<td>1.26±0.11</td>
</tr>
<tr>
<td>STZ+GL</td>
<td>227.45±32.41</td>
<td>126.34±10.13</td>
<td>46.23±6.00</td>
<td>34.46±1.72</td>
<td>1.99±0.20</td>
</tr>
<tr>
<td>STZ+LML500</td>
<td>197.11±8.34</td>
<td>138.23±8.08**</td>
<td>65.44±5.56*</td>
<td>34.32±1.32</td>
<td>1.14±0.16</td>
</tr>
<tr>
<td>STZ+LML250</td>
<td>191.23±8.83</td>
<td>141.35±7.04**</td>
<td>55.12±4.11*</td>
<td>43.00±2.24*</td>
<td>1.43±0.07</td>
</tr>
<tr>
<td>STZ+LML125</td>
<td>151.34±20.45**</td>
<td>159.37±4.04**</td>
<td>58.34±5.45*</td>
<td>44.00±3.49*</td>
<td>1.65±0.19</td>
</tr>
<tr>
<td>STZ+LMT500</td>
<td>155.43±20.34*</td>
<td>152.54±5.67**</td>
<td>85.72±5.44*</td>
<td>36.55±1.24*</td>
<td>0.79±0.08**</td>
</tr>
<tr>
<td>STZ+LMT250</td>
<td>166.34±6.00</td>
<td>129.24±4.08</td>
<td>52.86±2.34*</td>
<td>41.75±2.89*</td>
<td>1.44±0.09</td>
</tr>
<tr>
<td>STZ+LMT125</td>
<td>198.23±4.23</td>
<td>125.34±5.46</td>
<td>45.23±2.45</td>
<td>39.50±2.72*</td>
<td>1.75±0.05</td>
</tr>
</tbody>
</table>

Table 2: * and# are significant levels of difference at p<0.05 relative to control and STZ only respectively.

STZ-only group showed significantly higher (p<0.05) TC compared to other groups. TG level is significantly higher (p<0.05) in STZ-only group compared to GL, LML and LMT treated groups. LML treated groups showed significantly higher HDL compared to other groups other treatment groups. LDL is significantly higher (p<0.05) in STZ only group compared to all treatment groups. STZ-only group showed significantly higher (P<0.05) AI compared to all treatment groups. STZ+LMT500 treated group showed significantly lower (p<0.05) AI than all other groups.

3.3 ORGAN WEIGHT

STZ-only group showed significantly higher (p<0.05) TC compared to other groups. TG level is significantly higher (p<0.05) in STZ-only group compared to GL, LML and LMT treated groups. LML treated groups showed significantly higher HDL compared to other groups other treatment groups. LDL is significantly higher (p<0.05) in STZ only group compared to all treatment groups. STZ-only group showed significantly higher (P<0.05) AI compared to all treatment groups. STZ+LMT500 treated group showed significantly lower (p<0.05) AI than all other groups.
FIGURE 4: Graph A, B, C and D showing the weight of liver, kidney, heart and pancreas of experimental animals respectively. There was no significant difference in weight of liver, kidney and heart across the experimental groups. However, weight of pancreas in STZ-only, and STZ+GL groups showed significant reduction (p<0.05) compared to other groups.

CTR= control, LML= L. micranthus leaf extract, LMT= L. micranthus twig extract, STZ= streptozotocin, GL= glibenclamide.

* and # are p value >0.05 relative to control. Data is presented as mean (bars) ± standard error of mean (error bars).

3.5 Histopathological Observations

Following tissue microscopic examination, pancreatic tissues from all animals were evaluated and it was observed that the control group pancreas showed normal architecture, with intact acinar cell cytoplasmic and nuclear structures. In rats administered 65mg/kg body weight STZ to induce a diabetic state, it was observed that there was severe diffuse necrosis of both exocrine and endocrine pancreatic tissues. Although, the diabetic group treated with glibenclamide in a bid to reverse the destructive effect of Streptozocin treatment showed some multifocal

pancreatic necrosis, overall, the animals in this group showed severe acinar (exocrine) nuclei hyperchromasia, possibly an indication of increased acinar cells’ nuclei activity. The pancreas of STZ induced diabetic rats treated with L. micranthus leaf extract showed mostly normal acinar cells (figure 1D). The pancreas of STZ induced diabetic rats treated with L. micranthus twig extract showed bridging pancreatic necrosis admixed normal acinar regions (figure 1E), implying normal pancreatic tissue admixed necrotic tissue.
DISCUSSION

Diabetes mellitus (DM) is a serious chronic disease, with heavy cost implication on human population globally [8]. This has heightened the search for alternative therapies with potentially low toxicity, and hence better safety profile, for the treatment of the disease, to improve the quality of life of diabetic patients, and/or reverse diabetic complications.

Gas chromatography – mass spectrophotometric (GC-MS) analysis showed the presence of different compounds in the twig and leaf extract at varying concentrations. This suggests that the presence of these compounds could be contributory to their unique antidiabetic activity. Leaf extract showed the presence of higher concentration of palmitic methyl ester which has been reported to possess several antidiabetic properties including activation of peroxisome proliferator-activated receptor (PPAR) family [31] and inhibition of α-amylase and α-glucosidase [32]. Other components such as Thymol, linalool,
camphor, and benzoic acid derivatives, have shown good antioxidant and antidiabetic potentials [33, 34, 35]. Thirteen compounds were found to be common in both leaf and twig extract of L. micranthus.

Acute toxicity study of both the leaf and the twig extract showed that both were safe at the maximum concentration (2000mg/kg body weight) employed. This finding supports previous safety study on L. micranthus [36]. This showed that the methanolic extracts of the both leaf and twig of L. micranthus are safe at the doses administered to the animals.

One of the mechanisms of action of antidiabetic agents include: causing reduction in glucose absorption from the gastrointestinal tract (GIT) [37]. This was assessed by evaluating the in vitro inhibitory effect of LML and LMT on starch degrading enzymes (α-amylase and α-glucosidase). Clinically used antidiabetic drugs, such as Acorbose and miglitol inhibit both enzymes and reduce the rate of digestion of complex carbohydrates but this is accompanied by gastrointestinal discomforts [38]. Management of blood glucose level is a critical strategy in the control of diabetes and its complications, this makes leaf and twig extracts of L. micranthus potential candidates for controlling glucose release at GIT level. Both extracts could prevent postprandial spikes that have been implicated in cardiovascular and macro-vascular complications of diabetes[39]. The twig extract showed better inhibitory effect on α-amylase and α-glucosidase compared to the leaf extract.

STZ-induced hyperglycemia was established in all diabetic groups in order to evaluate the effect of LMT and LML on treatment groups. The significant weight loss (p<0.05) in all STZ-induced diabetic groups could be strongly linked to STZ-induced destruction of beta cells of the islets of langerhans of the pancreas; the attending abolition of insulin production and secretion, and resultant decreased glucose uptake and storage [40,41]. The destruction of the pancreas resulted in utilization of non-carbohydrates nutrients such as proteins and fatty acid for the synthesis of glucose. The loss of structural proteins as a result of increased gluconeogenesis together with increased glycolysis and increased synthesis of ketone bodies results in severe weight loss in diabetic animals [40, 41]. L. micranthus extracts- and glibenclamide treated groups showed similar weight gain pattern which is indicative of the ameliorating effect of the treatments on weight loss in STZ-induced diabetic rats. The effects of the extracts in ameliorating STZ-induced weight loss has been reported for borneol, cavanol and Sweetianmarine [42,43,44]. Twig and leaf extract of L. micranthus may contain principles useful in ameliorating weight loss seen in Type-1 DM.

Persistent hyperglycemia is a major factor in the pathophysiology of DM. Hypoglycemic agents should possess the ability to reduce the fasting blood glucose in diabetic patients. From the presents study, the fasting blood glucose of all animals in different groups at the start of the experiment were not significantly different (p>0.05). After induction of diabetes, the diabetic groups showed significant hyperglycemia which could be attributed to destruction of pancreatic beta cells, causing reduction in insulin production and hence, poor glucose utilization. The result showed adequate control of hyperglycemia in the glibenclamide-treated group and the L. micranthus leaf and twig-extract treated groups. The hypoglycemic effect of the extracts was observed at day 7 of treatment, and was consistent up to day 14 of treatment, suggesting that the extracts could be used for management of DM-induced hyperglycemia. This is consistent with the previous studies in alloxan-induced diabetes [45,46].

The effect of glibenclamide, LML and LMT on glucose utilization assessed by the oral glucose tolerance test (OGTT) exhibited comparable glucose utilization pattern to norglucogenic group. This showed that both leaf and twig extracts of L. micranthus had similar effect on glucose utilization comparable to glibenclamide (p<0.05).

DM impairs glycogen synthesis both in the rat’s liver and skeletal muscles [47]. The glycogen content of skeletal muscle and liver are markedly decreased in DM [48]. Result of the present study showed increase in the liver glycogen content of all extract-treated animals compared to the diabetic untreated group. LMT treated animal showed significantly (p<0.05) higher liver glycogen levels compared to other groups. Normal control group, LML500 and STZ-LML500 groups showed similar liver glycogen levels. This showed that the leaf and twig extracts of L. micranthus could improve glycogen storage possibly by inducing glycogenesis or reducing glycogenolysis in DM. This activity has been reported for borneol, citornellol and mytenal [42, 49, 50, 51] which were monoterpenes derived from different plants with antidiabetic activities.

The damaging effect of streptozotocin on pancreatic beta cells resulted in reduction in the level of serum insulin of the diabetic untreated rats compared to the control, glibenclamide-treated and L. micranthus extract-treated diabetic rats. LML500 treated diabetic rats showed higher serum insulin level than glibenclamide (an insulin secretagogue) [52] and LMT 500. Thus suggesting that leaf extract of L. micranthus has better insulin-secreting activity than the twig and glibenclamide-treated group. The result correlate with the findings of Gray and Platt [53].

LML500 and LMT500 extracts had significantly higher (p<0.05) effect at reducing haemoglobin glycation comparable to glibenclamide. Clinical studies have shown that glycated hemoglobin is higher in diabetic patients than in non-diabetic individuals [54]. In the present study, reduction in haemoglobin glycation by the extracts could also be attributed to the activity in stimulating insulin secretion, or increasing glycogenesis and glucose utilization, leading to reduced blood glucose level and reduction in the rate of haemoglobin glycation. In addition, the antioxidant effect on phytochemicals in L. micranthus extracts similar to what was reported for D-limonene and thymol in previous studies [55,56] could play a role.

The role of tumor necrotic factor-α (TNF-α), an adipocytokine in systemic inflammation has been established in DM [57,58]. LML500 and LMT500-treated diabetic group showed a significantly lower (p<0.05) TNF-α level compared to all other groups. Results from the present study also showed that L. micranthus leaf extract exhibited better serum TNF-α lowering effect than glibenclamide. The leaf and twig extracts of L. micranthus may reduce diabetic complications by exerting anti-inflammatory activity and lowering levels of TNF-α in inflammatory and metabolic diseases such as DM. Similar effect has been reported in adipocyes for geniposide [59].

Dyslipidemia is a critical feature of uncontrolled DM, characterized by high total cholesterol (TC), low density lipoprotein (LDL) cholesterol and triglycerides, and a reduction in the level of high density lipoprotein (HDL) cholesterol [14]. Acute insulin deficiency initially causes an increase in free fatty acid mobilization from adipose tissue resulting in an increased production of LDL cholesterol particles and resultant dyslipidemia [60, 61, 62]. LML500 and LMT500 showed similar control of the TC, LDL and serum triglyceride level at all doses used. Similarly, hypercholesterolemia observed in diabetic-untreated groupwere lowered in glibenclamide, LML and LMT treated groups. In addition, HDL cholesterol level was significantly increased (p<0.05) in extract-treated animals than glibenclamide-treated group. Thus, suggesting a role for the extracts in the management of diabetic-induced dyslipidemia. Similar effect has been reported for D-Limonene and thymol [44, 55].
Atherogenic index is a predictor of atherosclerosis, resulting from the imbalance between HDL and total cholesterol. Atherosclerosis is a major contributor to the global morbidity and mortality, both in hypertensive and diabetic individuals [63, 64]. LML-treated groups showed atherogenic index significantly lower (p<0.05) than the glibenclamide treated group. The extracts showed potent antidiabetic effect. The extracts may therefore be useful at reducing the risk of cardiovascular, and vascular events and death that are complications of chronic DM.

Analysis of weight of organs showed no significant difference (p>0.05) in the weight of the liver, heart and kidney of all experimental groups. Weight of pancreas for the STZ-diabetic untreated group was significantly lower (p<0.05) compared to weights of the pancreas in all other experimental groups. The increase in the weight of pancreas of LML500 treated group suggests that LML contain active phytochemicals that are capable of regenerating pancreatic beta cells. Further studies are required to confirm this finding.

The histopathological photomicrograph of the pancreas of experimental animals in this study re-enforces the destructive nature of STZ on both exocrine and endocrine pancreatic tissues, as it caused necrosis in these tissues. Also, the efficacy of glibenclamide in the treatment/management of diabetic state was shown to be partly due to increased activity of the islet and acinar cells which in the present study were observed to be hyperchromatic. This study demonstrates the ameliorating effect of L. micranthus leaf and twig extracts on the STZ-induced destruction of acinar and beta cells of the pancreas. Similar effects has been reported for menthol and paminic acid ester [31, 51, 65].

In conclusion, this study showed the therapeutic benefits of L. micranthus in management of, and prevention of complications of DM via different mechanisms. Further studies are required to identify the phytochemical principles responsible for these antidiabetic actions and their possible mechanisms of action tested.

Acknowledgement

We acknowledge the staff of Central Research Laboratory, Animal House and Chemical Engineering Department, University of Ilorin, Ilorin for their contributions to this work. We also acknowledge Mr Femi Adesua of Department of Pharmacology and Therapeutics, University of Ilorin, Ilorin for his contributions in the extract preparation.

Conflict of Interest

The authors of this manuscript declare that there is no conflict of interest.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or Not-for-profit sectors.

References


22. Osadebe PO, Omeje EO, Uzor PF, David EK, Ohiorah DC. (2010). Seasonal variation for the antidiabetic activity of Loranthus
28. Friedewald, WT, Levy RI, Fredrickson DS. (1972). Estimation of
27. Friedewald, WT, Levy RI, Fredrickson DS. (1972). Estimation of